Rogers S, Day C A, Fox S B
Department of Pathology, University of Sheffield Medical School, UK.
Hum Pathol. 1993 Feb;24(2):148-51. doi: 10.1016/0046-8177(93)90293-p.
Male breast cancer is probably hormone dependent, but studies are few due to the rarity of this tumor. We have studied 21 cases of male breast cancer immunohistologically for estrogen receptor (ER) and cathepsin D (CD) expression. In carcinoma of the female breast ER expression is associated with longer patient survival and responsiveness to hormonal manipulation. Cathepsin D is an estrogen-regulated lysosomal protease with proteolytic and mitogenic properties whose presence denotes a functioning ER. In our series of male breast carcinomas 86% were ER positive and 62% were CD positive; this compares with typical figures of 50% and 66%, respectively, for female breast cancer. We observed no trends between expression of ER and CD and patient survival; immunostaining for ER and CD is unlikely to be clinically useful in carcinoma of the male breast. The high rate of ER positivity in males suggests that male and female breast carcinomas are biologically different tumors.
男性乳腺癌可能依赖激素，但由于这种肿瘤罕见，相关研究较少。我们对21例男性乳腺癌患者进行了雌激素受体（ER）和组织蛋白酶D（CD）表达的免疫组织化学研究。在女性乳腺癌中，ER表达与患者较长的生存期及对激素治疗的反应性相关。组织蛋白酶D是一种受雌激素调节的溶酶体蛋白酶，具有蛋白水解和促有丝分裂特性，其存在表明ER功能正常。在我们的男性乳腺癌系列研究中，86%为ER阳性，62%为CD阳性；相比之下，女性乳腺癌的典型比例分别为50%和66%。我们未观察到ER和CD表达与患者生存期之间的趋势；ER和CD免疫染色在男性乳腺癌中不太可能具有临床实用性。男性中ER阳性率较高表明男性和女性乳腺癌在生物学上是不同的肿瘤。
